Literature DB >> 21302490

[Clinical observation on treatment of infantile rotavirus enteritis by umbilical application of lunxieting paste].

Ying Wu1, Wan-qiang Chen, Yu Jin.   

Abstract

OBJECTIVE: To observe the clinical effect of umbilical application with Lunxieting Paste (LXT) for the treatment of infantile rotavirus enteritis (IRE).
METHODS: One hundred and ninety infants with IRE were randomly assigned into three groups, 55 in Group A, 60 in Group B and 75 in Group C. All were treated with conventional therapy, mainly the dehydration and acidosis correcting, rehydration salt and antiviral therapy; but to patients in Groups B and C, an additional medication of Smecta 1.5 g, thrice a day. for infants below 1 year and 3 g, thrice a day. for those between 1-2 years old, by orally taken with 0.05 L of warm water and umbilical application with LXT (one dose per day, containing 6.0 g of crude drug) was given respectively.
RESULTS: The total effective rate was 69.1% in Group A, 75% in Group B and 92% in Group C, respectively, showing significant difference (P<0.05) in comparing Group C with Groups A and B. Moreover, serum levels of TNF-alpha were decreased and IFN-gamma increased in Group C after treatment, all showed statistical significance as compared with those in the other two groups (P<0.05). No significant adverse reactions were observed in all patients.
CONCLUSION: Umbilical application of LXT could effectively alleviate the diarrhea symptom in IRE patients, accelerate the negative inversion of rotavirus, and reduce the injury of intestinal membrane, showing a therapeutic efficacy more effective and quicker than that of conventional treatment with more convenience for use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21302490

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  1 in total

1.  The effects of linalool acupoint application therapy on sleep regulation.

Authors:  Lei Xu; Xiaofei Li; Yumeng Zhang; Meng Ding; Baoshan Sun; Guangyue Su; Yuqing Zhao
Journal:  RSC Adv       Date:  2021-02-03       Impact factor: 3.361

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.